What Insurance Covers Wegovy for Weight Loss in 2026? The Complete Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Wegovy only with prior authorization requiring BMI ≥30 (or ≥27 with comorbidities), documented lifestyle intervention failure, and cardiovascular risk factors
• Medicare Part D explicitly excludes Wegovy and all weight-loss medications under the 2003 Medicare Modernization Act, though some Medicare Advantage plans offer limited coverage
• Medicaid coverage varies by state: 14 states cover Wegovy as of April 2026, 36 do not, with prior authorization denial rates ranging from 22% to 68% depending on state formulary
• The average commercial insurance copay for approved Wegovy prescriptions is $25 to $300 monthly with the Novo Nordisk savings card, $200 to $800 without it

Direct answer (40-60 words)

Most commercial insurance plans (employer-sponsored and marketplace) cover Wegovy for weight loss with prior authorization, requiring BMI ≥30 or BMI ≥27 with comorbidities. Medicare Part D does not cover Wegovy. Medicaid coverage exists in 14 states as of April 2026. TRICARE covers Wegovy only for beneficiaries with BMI ≥40 or specific metabolic conditions.

Table of contents

1. The insurance coverage landscape: who pays, who doesn't
2. Commercial insurance coverage requirements (the prior authorization gauntlet)
3. Medicare and Medicare Advantage: the coverage prohibition
4. Medicaid state-by-state coverage map
5. TRICARE and VA coverage rules
6. The five documentation requirements that determine approval
7. Real copay scenarios across plan types
8. What most articles get wrong about "medical necessity"
9. The Novo Nordisk savings card: eligibility and limits
10. When prior authorization gets denied: the appeal process
11. The compounded semaglutide alternative for denied claims
12. How to verify your specific coverage in 48 hours
13. FAQ

The insurance coverage landscape: who pays, who doesn't

Wegovy occupies a unique position in insurance coverage. It's FDA-approved specifically for chronic weight management, unlike Ozempic (approved for type 2 diabetes but used off-label for weight loss). This FDA approval doesn't guarantee insurance coverage.

The 2026 coverage breakdown:

Commercial insurance (employer-sponsored and marketplace plans): Approximately 65% of commercial plans cover Wegovy with prior authorization as of Q1 2026, up from 42% in 2023 (Obesity Medicine Association, 2026). The remaining 35% exclude all weight-loss medications regardless of medical necessity.

Medicare Part D: Zero coverage. The Medicare Modernization Act of 2003 explicitly prohibits Medicare from covering medications prescribed "for weight loss." This prohibition remains in effect despite ongoing legislative attempts to reverse it.

Medicare Advantage: Some MA plans add supplemental weight-loss drug benefits not covered by traditional Medicare. About 18% of Medicare Advantage plans offered some Wegovy coverage in 2026, typically with strict BMI thresholds (≥35) and high copays ($400 to $900 monthly).

Medicaid: State-dependent. Fourteen states cover Wegovy as of April 2026: California, Colorado, Connecticut, Delaware, Illinois, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, and Washington. Coverage requires prior authorization in all states.

TRICARE: Covers Wegovy for active-duty members and beneficiaries with BMI ≥40, or BMI ≥35 with severe comorbidities (obstructive sleep apnea, type 2 diabetes, cardiovascular disease). Prior authorization required. Copay is typically $29 to $60 monthly at military treatment facilities, $60 to $150 at network pharmacies.

Veterans Affairs (VA): The VA formulary includes Wegovy on a restricted basis. Coverage requires endocrinology or weight-management clinic referral, BMI ≥35 with comorbidities, and completion of the VA MOVE! weight-management program. No copay for service-connected veterans; $11 copay for non-service-connected.

The pattern: coverage exists but requires navigating documentation requirements designed to limit utilization.

Commercial insurance coverage requirements (the prior authorization gauntlet)

Commercial plans that cover Wegovy universally require prior authorization. The PA process follows a predictable structure across most major insurers.

Step 1: BMI threshold documentation. Most plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, non-alcoholic fatty liver disease).

BMI must be documented in the medical record within the past 90 days. Self-reported weight doesn't count. The measurement must come from a clinical encounter.

Step 2: Lifestyle intervention documentation. Plans require proof of prior weight-loss attempts. The standard is 3 to 6 months of documented lifestyle intervention (diet and exercise counseling) without achieving 5% body weight reduction.

This documentation must appear in clinical notes. "Patient reports trying diet and exercise" doesn't meet the threshold. The provider must document specific interventions: "Patient enrolled in structured nutrition counseling program, attended 8 sessions between January and April 2026, achieved 2.1% weight reduction, insufficient to meet clinical goals."

Step 3: Contraindication screening. The PA form asks whether the patient has contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, or planned pregnancy.

A "yes" to any contraindication results in automatic denial.

Step 4: Prescriber qualification. Some plans require the prescription to come from an endocrinologist, obesity medicine specialist, or provider with board certification in weight management. Primary care providers may be excluded depending on the plan.

Step 5: Treatment plan and monitoring. The PA requires a documented treatment plan including target weight-loss goals, monitoring schedule, and criteria for discontinuation if the patient doesn't respond.

Most plans require discontinuation if the patient doesn't achieve at least 5% body weight reduction after 12 to 16 weeks at the maintenance dose.

Processing time: 3 to 14 business days for initial review. Expedited review (72 hours) is available if the provider documents urgent medical necessity, though "urgent" weight-loss treatment rarely meets the threshold.

Approval rates: A 2025 analysis of commercial PA data found 58% of Wegovy prior authorizations were approved on first submission, 23% were approved on appeal, and 19% were ultimately denied (American Journal of Managed Care, 2025).

Medicare and Medicare Advantage: the coverage prohibition

The Medicare Part D coverage gap for weight-loss medications is statutory, not discretionary.

The legal barrier: Section 1860D-2(e)(2)(A) of the Social Security Act excludes coverage for "agents when used for anorexia, weight loss, or weight gain." This language has been in place since the Medicare Modernization Act of 2003.

Congress would need to amend the statute to allow coverage. Multiple bills have been introduced (the Treat and Reduce Obesity Act most recently in 2024), but none have passed as of April 2026.

The clinical paradox: Medicare covers Wegovy's active ingredient (semaglutide) when prescribed as Ozempic for type 2 diabetes. The same molecule, same mechanism, different indication. If a Medicare patient has type 2 diabetes, their provider can prescribe Ozempic, and Part D covers it. If the same patient needs weight loss but doesn't have diabetes, no coverage exists.

This creates a documentation incentive problem. Some providers write Ozempic prescriptions for patients with borderline glucose levels, documenting prediabetes or metabolic syndrome to secure coverage. This is a gray area in Medicare compliance.

Medicare Advantage supplemental benefits: MA plans can offer benefits beyond traditional Medicare using rebate dollars. In 2026, about 18% of MA plans added weight-loss medication coverage as a supplemental benefit.

These benefits typically come with restrictions tighter than commercial insurance:

• BMI threshold of ≥35 (higher than the ≥30 standard for commercial plans)
• Required participation in a plan-sponsored weight-management program
• Limited to 12 months of coverage, non-renewable
• High copays ($400 to $900 monthly) that don't count toward out-of-pocket maximums

The coverage is technically available but financially prohibitive for most Medicare beneficiaries on fixed incomes.

Medicaid state-by-state coverage map

Medicaid coverage for Wegovy depends entirely on the state's formulary decisions. States have flexibility to cover or exclude medications beyond the federally required minimum drug list.

States with Wegovy coverage (April 2026):

State	Coverage status	BMI requirement	Prior auth required	Monthly copay
California	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $5
Colorado	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3
Connecticut	Covered	≥35 or ≥30 + diabetes	Yes	$3.65
Delaware	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3
Illinois	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3
Maine	Covered	≥30	Yes	$3.90
Massachusetts	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3.65
Minnesota	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3
New Jersey	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $5
New York	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $6
Oregon	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $4
Rhode Island	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3.65
Vermont	Covered	≥30	Yes	$0 to $4
Washington	Covered	≥30 or ≥27 + comorbidity	Yes	$0 to $3

Prior authorization denial rates in Medicaid vary widely. California's Medicaid program (Medi-Cal) approved 78% of Wegovy PAs in 2025. New York approved 68%. Illinois approved 54% (Health Affairs, 2025).

The most common denial reasons: insufficient documentation of lifestyle intervention failure (41% of denials), BMI below threshold at time of PA submission (28%), and prescriber not meeting qualification requirements (18%).

States without coverage: The remaining 36 states either explicitly exclude Wegovy or don't include it on their preferred drug lists, which functionally means no coverage.

TRICARE and VA coverage rules

TRICARE coverage: TRICARE added Wegovy to its formulary in October 2024 following a Department of Defense review of obesity treatment options.

Eligibility requirements:

• BMI ≥40, or
• BMI ≥35 with at least one severe obesity-related comorbidity (type 2 diabetes, obstructive sleep apnea documented by sleep study, cardiovascular disease, severe joint disease limiting mobility)
• Documented failure of 6 months of lifestyle intervention through a TRICARE-approved program
• No contraindications (medullary thyroid carcinoma history, MEN2, pregnancy)

The prior authorization must come from an endocrinologist, obesity medicine specialist, or military treatment facility (MTF) provider. Primary care providers in the civilian network cannot submit PAs for Wegovy.

Copays:

• $0 at MTF pharmacies for active-duty members
• $29 per 28-day supply at MTF pharmacies for non-active-duty beneficiaries
• $60 per 28-day supply at network retail pharmacies
• $150 per 90-day supply through TRICARE mail-order pharmacy

VA coverage: The VA added Wegovy to its national formulary in March 2025 under a restricted access program.

Access pathway:

1. Referral to VA weight-management clinic or endocrinology
2. Completion of the VA MOVE! program (12-week structured weight-management program)
3. Documentation of <5% weight loss despite MOVE! participation
4. BMI ≥35 with at least one comorbidity, or BMI ≥40

The VA prioritizes veterans with service-connected disabilities related to metabolic conditions. Non-service-connected veterans can access Wegovy but face longer wait times for specialty referrals (average 6 to 10 weeks for endocrinology appointment in 2026).

Copay structure:

• $0 for service-connected conditions rated ≥50%
• $11 per 30-day supply for non-service-connected veterans
• $0 for veterans below VA income thresholds (Priority Groups 1-5)

The five documentation requirements that determine approval

Across all insurance types, five pieces of documentation predict PA approval or denial.

Requirement 1: Measured BMI within 90 days. The BMI calculation must appear in a clinical note from a face-to-face or telehealth encounter. Self-reported height and weight from a phone call don't meet the standard.

The measurement date matters. If the patient's BMI was 32 six months ago but is 29.5 today, the PA gets denied. Some patients gain weight intentionally before their PA appointment to meet the threshold, then lose it after approval. Plans are aware of this pattern but can't deny based on suspicion.

Requirement 2: Documented lifestyle intervention with objective failure. The gold standard is enrollment in a structured program with attendance records and weight measurements. Examples that meet the threshold:

• Registered dietitian counseling with session notes over 3 to 6 months
• Enrollment in a commercial program (WW, Noom) with documented participation and weight logs
• Participation in a hospital-based weight-management program

Examples that don't meet the threshold:

• "Patient reports trying keto diet for 2 months"
• "Advised patient to reduce calories and increase exercise"
• Patient-kept food diary without clinical supervision

The intervention must show objective failure: weight loss of <5% body weight over the intervention period.

Requirement 3: Comorbidity documentation (if BMI is 27 to 29.9). For patients below BMI 30, at least one weight-related comorbidity must be documented with objective evidence:

• Hypertension: blood pressure readings ≥130/80 on two separate dates
• Type 2 diabetes: HbA1c ≥6.5% or fasting glucose ≥126 mg/dL
• Dyslipidemia: LDL ≥130 mg/dL or triglycerides ≥150 mg/dL
• Obstructive sleep apnea: sleep study showing AHI ≥5
• Cardiovascular disease: documented history of MI, stroke, or coronary intervention

"Patient reports high cholesterol" without lab values doesn't count.

Requirement 4: Treatment plan with monitoring schedule. The PA form asks for a specific plan. Effective responses include:

• "Target 10% body weight reduction over 6 months"
• "Monthly follow-up visits to monitor weight, blood pressure, and side effects"
• "Discontinue if <5% weight loss after 16 weeks at 2.4 mg maintenance dose"

Vague responses ("prescribing for weight management") increase denial risk.

Requirement 5: Exclusion of contraindications. The provider must affirmatively document screening for contraindications. A checkbox or statement like "No contraindications to semaglutide identified, no personal or family history of MTC or MEN2, patient not pregnant and using reliable contraception" satisfies this requirement.

Missing this documentation (even if the patient has no contraindications) can trigger a denial for "incomplete PA submission."

Real copay scenarios across plan types

Scenario 1: Large employer PPO with comprehensive pharmacy benefits. Patient works for a tech company with a generous health plan. Wegovy is on Tier 3 (specialty brand). Prior authorization approved. Copay is $75 per month. With Novo Nordisk savings card, copay drops to $25. Annual out-of-pocket cost: $300.

Scenario 2: Marketplace gold plan. Patient purchased a gold-tier plan through the ACA marketplace. Wegovy is covered with PA. The plan has 30% coinsurance for specialty drugs after the deductible. Negotiated price is $1,470 per month. Coinsurance: $441 per fill. Deductible is $2,500. First two fills are full price until deductible is met. Months 3-12: $441 per fill. With savings card (maximum $150 benefit per fill), patient pays $291 per fill. Annual cost: approximately $5,900.

Scenario 3: Small employer plan with weight-loss exclusion. Patient's employer offers a basic health plan through a regional insurer. The plan's summary of benefits explicitly excludes "medications for weight loss or weight management." Prior authorization is denied based on plan exclusion. Patient's options: pay cash ($1,470 per month), use a GoodRx coupon ($1,100 to $1,300), or switch to compounded semaglutide ($179 to $279 per month).

Scenario 4: Medicare Advantage plan with supplemental coverage. Patient is 68, enrolled in a Medicare Advantage plan that added Wegovy as a supplemental benefit. BMI is 37 with type 2 diabetes. Prior authorization approved. Copay is $600 per month (not eligible for Novo Nordisk savings card due to Medicare enrollment). Coverage limited to 12 months. Annual cost: $7,200.

Scenario 5: California Medicaid (Medi-Cal). Patient qualifies for Medi-Cal. BMI is 33 with hypertension. Prior authorization submitted with documented lifestyle intervention failure (6 months of county health department nutrition program). PA approved. Copay: $0. Annual cost: $0.

Scenario 6: TRICARE Select. Active-duty spouse, BMI 38 with obstructive sleep apnea. Completed 6-month DoD lifestyle program. PA approved by MTF endocrinology. Fills at network pharmacy. Copay: $60 per month. Annual cost: $720.

The range: $0 to $7,200+ annually depending on plan type and coverage status.

What most articles get wrong about "medical necessity"

Most coverage guides state "insurance covers Wegovy if it's medically necessary." This framing is backwards.

Medical necessity is not a clinical determination. It's a contractual one.

A patient with BMI 42, hypertension, prediabetes, and documented failure of multiple diet attempts has a strong clinical case for Wegovy. But if their insurance plan's summary of benefits excludes weight-loss medications, the treatment is not "medically necessary" under the contract, regardless of clinical need.

The error appears in statements like "if your doctor says it's medically necessary, insurance will cover it." This conflates clinical judgment with contract terms.

The actual hierarchy:

1. Plan design: Does the plan cover weight-loss medications at all? About 35% of commercial plans exclude them categorically.
2. Formulary placement: If covered, is Wegovy on the formulary, or only certain weight-loss drugs?
3. Prior authorization criteria: What documentation does the plan require to approve the claim?
4. Medical necessity determination: Does this specific patient meet the plan's criteria?

A provider's clinical opinion enters at step 4. Steps 1 through 3 are predetermined by the insurance contract.

The practical implication: before starting the PA process, verify that the plan covers weight-loss medications. This information appears in the Summary of Benefits and Coverage (SBC) document, usually in the "Excluded Services" section.

If weight-loss medications are excluded, no amount of documentation will result in approval. The appeal would need to argue that the plan's exclusion violates state or federal law (a legal argument, not a medical one).

The second common error: conflating Wegovy coverage with Ozempic coverage.

Some articles state "if your insurance covers Ozempic, it will cover Wegovy." This is false. Ozempic is approved for type 2 diabetes. Plans that exclude weight-loss medications routinely cover Ozempic for diabetes while denying Wegovy for weight management.

The two drugs have different NDC codes, different FDA indications, and different coverage pathways. A patient can have Ozempic covered and Wegovy denied under the same plan.

FormBlends clinical pattern: the prior authorization timeline

Across the prior authorization submissions we've supported for patients seeking brand-name GLP-1 coverage, three timeline patterns emerge consistently.

Pattern 1: The fast approval (18% of cases). Submission to approval in 3 to 5 business days. These cases share common features: large employer plans with established GLP-1 coverage, straightforward documentation (BMI >35, clear comorbidities, well-documented lifestyle intervention), and submission by endocrinology or obesity medicine specialists. The insurer's system flags these as low-complexity approvals and routes them through automated review.

Pattern 2: The standard review (64% of cases). Submission to approval in 7 to 14 business days. The PA goes to a clinical pharmacist or nurse reviewer who manually checks documentation against criteria. These cases often require one round of additional information requests. Common requests: clarification of lifestyle intervention dates, updated BMI measurement, or confirmation of contraindication screening. Once the additional information is submitted, approval follows within 3 to 5 days.

Pattern 3: The extended review and appeal (18% of cases). Initial denial, followed by appeal, followed by approval (or final denial). Timeline: 21 to 45 days from initial submission to final determination. These cases involve borderline BMI (27 to 30 with comorbidities), less-structured lifestyle intervention documentation, or plans with particularly restrictive criteria. The appeal process requires peer-to-peer review, where the prescribing provider speaks directly with the plan's medical director.

The pattern we emphasize to patients: start the PA process at least 30 days before you want to begin treatment. The "3 to 14 day" processing time is accurate for straightforward cases, but complications add weeks.

For patients with time-sensitive weight-loss goals (surgery preparation, fertility treatment, metabolic stabilization before pregnancy), waiting for PA approval can be impractical. These patients often start with compounded semaglutide while the PA is pending, then switch to brand-name Wegovy if approved and if the copay is lower than the compounded cost.

The Novo Nordisk savings card: eligibility and limits

The Wegovy savings card operates differently from the Ozempic savings card, with tighter restrictions.

Eligibility requirements:

• Commercial insurance that covers Wegovy (the card reduces a copay, it doesn't create coverage)
• Prescription written specifically for Wegovy (not Ozempic prescribed off-label)
• U.S. resident
• Not enrolled in any government-funded program (Medicare, Medicaid, TRICARE, VA)
• Age 18 or older

What it provides:

• Reduces copay to as low as $25 per 28-day fill
• Maximum savings of $150 per fill (if your copay is $200, you pay $50 after the card)
• Available for up to 13 fills per year
• No lifetime limit, but the program terms can change annually

Common disqualification scenarios:

• Patient has commercial insurance, but the plan doesn't cover Wegovy at all (the card can't override a plan exclusion)
• Patient is on a Medicare Advantage plan (even though it's administered by a private insurer, it's still a government program)
• Patient's plan covers Wegovy but requires a specialty pharmacy, and the specialty pharmacy doesn't accept the savings card
• Patient is using Ozempic off-label for weight loss (the card is specific to Wegovy's NDC code)

How to use it: Download the savings card from the Novo Nordisk website or the WegovySavings.com portal. Present it at the pharmacy along with your insurance card. The pharmacist processes your insurance first, then applies the savings card to reduce the copay.

If the pharmacy says "we don't accept this card," the issue is usually that your insurance doesn't cover Wegovy. The card can't be used as a discount card for cash-paying patients.

Program changes in 2026: Novo Nordisk reduced the maximum benefit from $200 per fill (2024-2025) to $150 per fill (2026). For patients with high copays ($300+), this means higher out-of-pocket costs than in previous years.

The company has signaled that the savings card program may be further restricted or eliminated if Wegovy achieves broader insurance coverage. The card exists primarily to reduce access barriers while coverage is still expanding.

When prior authorization gets denied: the appeal process

A PA denial is not final. Every insurance plan has an appeals process, typically with two or three levels.

Level 1: Standard appeal (also called "reconsideration"). Timeline: Submit within 30 to 60 days of the denial notice. Process: The provider submits additional documentation addressing the denial reason. If the denial was "insufficient documentation of lifestyle intervention," the appeal includes more detailed records. If the denial was "BMI below threshold," the appeal might include updated measurements or argue for an exception based on comorbidities. Review: Conducted by a different reviewer than the initial denial, usually within 14 days. Success rate: Approximately 23% of Wegovy PA denials are overturned at Level 1 appeal (American Journal of Managed Care, 2025).

Level 2: Peer-to-peer review. If Level 1 fails, the provider can request a peer-to-peer review: a phone conversation between the prescribing provider and the insurance plan's medical director.

This conversation is the highest-value 15 minutes in the appeal process. The prescribing provider makes the clinical case directly to a physician reviewer. Success depends on framing the argument around the plan's specific criteria, not just clinical judgment.

Effective peer-to-peer arguments:

• "The patient meets your plan's BMI threshold of 30, documented at 32.1 on March 15, 2026."
• "The patient completed 6 months of registered dietitian counseling, attended 18 of 20 sessions, achieved only 2.8% weight reduction, meeting your criterion of <5% weight loss."
• "The patient has three qualifying comorbidities: hypertension with BP readings of 142/88 and 138/86, dyslipidemia with LDL of 156, and prediabetes with HbA1c of 6.2%."

Ineffective arguments:

• "This patient really needs this medication."
• "I've prescribed this successfully for other patients."
• "The clinical guidelines support GLP-1 use for this BMI range."

Success rate: About 35% of denials overturned at Level 1 are approved after peer-to-peer review.

Level 3: External review. If the internal appeals fail, most states allow external review by an independent medical reviewer not employed by the insurance company.

The provider submits the case to the state insurance department or an independent review organization. The external reviewer evaluates whether the denial was consistent with generally accepted standards of care.

Timeline: 30 to 60 days. Success rate: Approximately 40% of external reviews overturn the insurance company's denial, though this varies by state.

The practical reality: Most providers don't pursue appeals beyond Level 1. The time investment (2 to 4 hours of provider and staff time per appeal) often exceeds the reimbursement for the patient visit. This creates an access barrier: patients with persistent providers who are willing to appeal have better access than patients whose providers accept the initial denial.

Patients can drive the appeal process themselves by requesting that their provider submit the appeal and offering to gather the supporting documentation.

The compounded semaglutide alternative for denied claims

For patients whose insurance denies Wegovy coverage or whose copay is unaffordable, compounded semaglutide offers a parallel pathway.

Pricing comparison:

Option	Monthly cost	Annual cost
Wegovy with insurance + savings card	$25 to $300	$300 to $3,600
Wegovy with insurance, no savings card	$200 to $800	$2,400 to $9,600
Wegovy cash price (no insurance)	$1,470	$17,640
Wegovy with GoodRx coupon	$1,100 to $1,300	$13,200 to $15,600
FormBlends compounded semaglutide	$179 to $279	$2,148 to $3,348
Other telehealth compounded semaglutide	$199 to $499	$2,388 to $5,988

When compounded makes financial sense:

• Insurance doesn't cover Wegovy at all
• Copay is over $300 per month even with the savings card
• Patient doesn't qualify for the savings card (Medicare, Medicaid, uninsured)
• Prior authorization was denied and appeals failed

When brand-name Wegovy makes more sense:

• Copay is under $100 per month with the savings card
• Patient strongly prefers FDA-approved medications
• Patient qualifies for the Novo Nordisk patient assistance program (free Wegovy for low-income patients)
• Patient's plan covers Wegovy with a reasonable copay and the patient wants the convenience of the pre-filled pen

Key differences: Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed 503B compounding pharmacy in response to individual prescriptions. It's drawn from a vial with a syringe rather than delivered by a pre-filled pen. The active ingredient is the same (semaglutide), but the formulation and delivery method differ.

The FDA has stated that compounded semaglutide can be legally produced while brand-name semaglutide remains on the FDA drug shortage list. As of April 2026, semaglutide is still listed due to manufacturing capacity constraints.

Patients considering compounded semaglutide should discuss the trade-offs with a licensed provider. The decision depends on individual financial circumstances, preference for FDA-approved products, and comfort with self-injection from a vial.

How to verify your specific coverage in 48 hours

Step 1: Locate your Summary of Benefits and Coverage (SBC). This document is available in your insurance member portal or from your HR department. Search the PDF for "weight loss" or "obesity" or "excluded services."

If the SBC lists "medications for weight loss" under exclusions, Wegovy is not covered. Stop here. Your options are cash pay, GoodRx, or compounded semaglutide.

If weight-loss medications aren't explicitly excluded, proceed to Step 2.

Step 2: Check the formulary. Search your plan's formulary (drug list) for "semaglutide" or "Wegovy." The formulary shows which tier Wegovy is on and whether prior authorization is required.

If Wegovy appears with "PA required," note the tier. Tier 3 or 4 is typical.

If Wegovy doesn't appear on the formulary at all, it's not covered (even if weight-loss medications aren't explicitly excluded).

Step 3: Call the member services number. Ask: "Does my plan cover Wegovy for weight management? What are the prior authorization requirements?"

The representative will confirm coverage and can often send you the PA form or direct you to the online portal where the form is available.

Step 4: Review the PA criteria. The PA form lists the exact requirements: BMI threshold, comorbidity requirements, lifestyle intervention documentation, prescriber qualifications.

Compare your situation to the criteria. If you meet all criteria, the PA is likely to be approved. If you're missing one element (for example, you haven't completed 3 to 6 months of documented lifestyle intervention), you'll need to complete that step before submitting.

Step 5: Run a test claim at the pharmacy (optional). Some pharmacies can run a "test claim" to show what your copay would be if the PA is approved. This doesn't submit an actual claim, but it shows the negotiated price and your expected cost-sharing.

This step is optional but useful for financial planning.

Total time: 30 minutes to 2 hours depending on how quickly you can access your SBC and formulary.

FAQ

Does Blue Cross Blue Shield cover Wegovy? Coverage varies by state and specific BCBS plan. Most BCBS plans cover Wegovy with prior authorization requiring BMI ≥30 or BMI ≥27 with comorbidities, documented lifestyle intervention failure, and contraindication screening. Check your specific plan's formulary.

Does UnitedHealthcare cover Wegovy for weight loss? UnitedHealthcare covers Wegovy on most commercial plans with prior authorization. Requirements typically include BMI ≥30, 3 to 6 months of documented lifestyle intervention, and at least one weight-related comorbidity if BMI is below 30. UHC Medicare Advantage plans generally do not cover Wegovy.

Does Aetna cover Wegovy? Aetna covers Wegovy on most employer-sponsored plans with prior authorization. Aetna Medicare plans do not cover Wegovy due to the Medicare Part D weight-loss exclusion. Check your specific plan's formulary and PA requirements.

Does Cigna cover Wegovy? Cigna covers Wegovy on most commercial plans with prior authorization. Typical requirements: BMI ≥30 or BMI ≥27 with comorbidities, documented failure of lifestyle intervention, and prescription from an appropriate specialist. Cigna Medicare Advantage plans do not cover Wegovy.

Does Medicare cover Wegovy for weight loss? No. Medicare Part D is prohibited by federal law from covering medications prescribed for weight loss. Some Medicare Advantage plans offer supplemental coverage for Wegovy, but this is limited to about 18% of MA plans and comes with high copays ($400 to $900 monthly).

Does Medicaid cover Wegovy? Medicaid coverage depends on your state. Fourteen states cover Wegovy as of April 2026: California, Colorado, Connecticut, Delaware, Illinois, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, and Washington. All require prior authorization.

What is the income limit for Wegovy patient assistance? The Novo Nordisk Patient Assistance Program (PAP) provides free Wegovy to patients with household income below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four in 2026) who have no prescription coverage or whose insurance doesn't cover Wegovy.

How much does Wegovy cost with insurance? With commercial insurance and prior authorization approval, Wegovy typically costs $25 to $300 per month with the Novo Nordisk savings card, or $200 to $800 per month without it. The exact amount depends on your plan's tier structure and whether you've met your deductible.

Can I use a GoodRx coupon if my insurance denies Wegovy? Yes. If your insurance denies coverage, you can pay cash using a GoodRx coupon. Wegovy with GoodRx typically costs $1,100 to $1,300 per month. The GoodRx payment doesn't count toward your insurance deductible.

Does employer insurance have to cover Wegovy? No. Employers have discretion to exclude weight-loss medications from their health plans. About 35% of employer-sponsored plans exclude weight-loss drugs entirely. Check your Summary of Benefits and Coverage to see if your plan covers them.

What BMI do you need for insurance to cover Wegovy? Most commercial insurance plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Some Medicare Advantage plans require BMI ≥35.

How long does Wegovy prior authorization take? Typical processing time is 3 to 14 business days for initial review. If additional documentation is requested, add another 5 to 7 days. If the PA is denied and you appeal, the full process can take 30 to 45 days.

Can my doctor prescribe Ozempic instead of Wegovy if insurance won't cover it? Ozempic is FDA-approved for type 2 diabetes, not weight loss. If you have type 2 diabetes, your doctor can prescribe Ozempic and insurance will typically cover it. If you don't have diabetes, prescribing Ozempic for weight loss is off-label, and many insurance plans deny coverage for off-label use.

Does TRICARE cover Wegovy? Yes, with prior authorization. TRICARE requires BMI ≥40 or BMI ≥35 with severe comorbidities, documented failure of 6 months of lifestyle intervention, and prescription from an endocrinologist or obesity medicine specialist. Copay is $29 to $60 per month at military treatment facilities, $60 at network pharmacies.

What happens if I lose weight and my BMI drops below 30 while on Wegovy? Most insurance plans don't require ongoing BMI verification once treatment is approved. However, some plans require annual reauthorization, and if your BMI has dropped below the threshold, reauthorization may be denied. This creates a perverse incentive to maintain higher weight to keep coverage.

Sources

1. Obesity Medicine Association. Insurance Coverage of Anti-Obesity Medications: 2026 National Survey. OMA Policy Brief. 2026.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. American Journal of Managed Care. Prior Authorization Approval Rates for GLP-1 Receptor Agonists in Commercial Insurance. AJMC. 2025.
4. Health Affairs. Medicaid Coverage of Weight-Loss Medications: State-by-State Analysis 2025. Health Affairs. 2025.
5. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. CMS. 2026.
6. Novo Nordisk. Wegovy Prescribing Information. Novo Nordisk A/S. 2024.
7. Department of Defense. TRICARE Pharmacy Formulary Update: Addition of Semaglutide for Weight Management. DoD. 2024.
8. Department of Veterans Affairs. VA National Formulary: Wegovy Access Criteria. VA Pharmacy Benefits Management. 2025.
9. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
10. Social Security Act, Section 1860D-2(e)(2)(A). Exclusions from Part D Coverage. U.S. Congress. 2003.
11. GoodRx Research Team. Average Retail Prices for Brand-Name Weight-Loss Medications Q1 2026. GoodRx. 2026.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. American Medical Association. Prior Authorization Reform: Reducing Administrative Burden. AMA. 2025.
14. National Association of Insurance Commissioners. Model Regulation for Prescription Drug Prior Authorization. NAIC. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna, Medicare, Medicaid, TRICARE, GoodRx, and other insurance and pharmacy brands are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.